{"id":57797,"date":"2024-05-31T11:39:36","date_gmt":"2024-05-31T09:39:36","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=57797"},"modified":"2024-09-23T14:55:59","modified_gmt":"2024-09-23T12:55:59","slug":"our-2023-integrated-annual-report-is-live","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/general\/our-2023-integrated-annual-report-is-live\/","title":{"rendered":"Our 2023 Integrated Annual Report is live!"},"content":{"rendered":"\n
In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of \u20ac3.128bn. These results demonstrate that our strategy is delivering, as we move away from reliance on a single blockbuster to further developing our four robust growth platforms. <\/p>\n\n\n\t\n\t \n\t\t\t\t\t\t\t\t\t\t\t 2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.<\/p>\n\t\t\t\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t